DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Zhen Hong, Min Shi, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, James B. Leverenz, Geoffrey Baird, Thomas J. Montine, Aneeka M. Hancock, Hyejin Hwang, Catherine Pan, Joshua Bradner, Un Jung Kang, Poul H. Jensen, Jing Zhang

Research output: Contribution to journalArticle

402 Citations (Scopus)

Abstract

Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and α-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and α-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and α-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and α-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and α-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and α-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged ≥65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and α-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70 for DJ-1, and 92 and 58 for α-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or α-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or α-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and α-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration.

Original languageEnglish
Pages (from-to)713-726
Number of pages14
JournalBrain
Volume133
Issue number3
DOIs
StatePublished - 1 Mar 2010

Fingerprint

Synucleins
Parkinson Disease
Cerebrospinal Fluid
Biomarkers
Gel Chromatography
Disease Progression

Keywords

  • Biomarker
  • Cerebrospinal fluid
  • DJ-1
  • Parkinson's disease
  • α-synuclein

Cite this

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., ... Zhang, J. (2010). DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133(3), 713-726. https://doi.org/10.1093/brain/awq008
Hong, Zhen ; Shi, Min ; Chung, Kathryn A. ; Quinn, Joseph F. ; Peskind, Elaine R. ; Galasko, Douglas ; Jankovic, Joseph ; Zabetian, Cyrus P. ; Leverenz, James B. ; Baird, Geoffrey ; Montine, Thomas J. ; Hancock, Aneeka M. ; Hwang, Hyejin ; Pan, Catherine ; Bradner, Joshua ; Kang, Un Jung ; Jensen, Poul H. ; Zhang, Jing. / DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. In: Brain. 2010 ; Vol. 133, No. 3. pp. 713-726.
@article{205cf3138ebf4e9798dfaa5af79ab5c6,
title = "DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease",
abstract = "Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and α-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and α-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and α-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and α-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and α-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and α-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged ≥65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and α-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70 for DJ-1, and 92 and 58 for α-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or α-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or α-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and α-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration.",
keywords = "Biomarker, Cerebrospinal fluid, DJ-1, Parkinson's disease, α-synuclein",
author = "Zhen Hong and Min Shi and Chung, {Kathryn A.} and Quinn, {Joseph F.} and Peskind, {Elaine R.} and Douglas Galasko and Joseph Jankovic and Zabetian, {Cyrus P.} and Leverenz, {James B.} and Geoffrey Baird and Montine, {Thomas J.} and Hancock, {Aneeka M.} and Hyejin Hwang and Catherine Pan and Joshua Bradner and Kang, {Un Jung} and Jensen, {Poul H.} and Jing Zhang",
year = "2010",
month = "3",
day = "1",
doi = "10.1093/brain/awq008",
language = "English",
volume = "133",
pages = "713--726",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "3",

}

Hong, Z, Shi, M, Chung, KA, Quinn, JF, Peskind, ER, Galasko, D, Jankovic, J, Zabetian, CP, Leverenz, JB, Baird, G, Montine, TJ, Hancock, AM, Hwang, H, Pan, C, Bradner, J, Kang, UJ, Jensen, PH & Zhang, J 2010, 'DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease', Brain, vol. 133, no. 3, pp. 713-726. https://doi.org/10.1093/brain/awq008

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. / Hong, Zhen; Shi, Min; Chung, Kathryn A.; Quinn, Joseph F.; Peskind, Elaine R.; Galasko, Douglas; Jankovic, Joseph; Zabetian, Cyrus P.; Leverenz, James B.; Baird, Geoffrey; Montine, Thomas J.; Hancock, Aneeka M.; Hwang, Hyejin; Pan, Catherine; Bradner, Joshua; Kang, Un Jung; Jensen, Poul H.; Zhang, Jing.

In: Brain, Vol. 133, No. 3, 01.03.2010, p. 713-726.

Research output: Contribution to journalArticle

TY - JOUR

T1 - DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

AU - Hong, Zhen

AU - Shi, Min

AU - Chung, Kathryn A.

AU - Quinn, Joseph F.

AU - Peskind, Elaine R.

AU - Galasko, Douglas

AU - Jankovic, Joseph

AU - Zabetian, Cyrus P.

AU - Leverenz, James B.

AU - Baird, Geoffrey

AU - Montine, Thomas J.

AU - Hancock, Aneeka M.

AU - Hwang, Hyejin

AU - Pan, Catherine

AU - Bradner, Joshua

AU - Kang, Un Jung

AU - Jensen, Poul H.

AU - Zhang, Jing

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and α-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and α-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and α-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and α-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and α-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and α-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged ≥65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and α-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70 for DJ-1, and 92 and 58 for α-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or α-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or α-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and α-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration.

AB - Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and α-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and α-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and α-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and α-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and α-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and α-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged ≥65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and α-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70 for DJ-1, and 92 and 58 for α-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or α-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or α-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and α-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration.

KW - Biomarker

KW - Cerebrospinal fluid

KW - DJ-1

KW - Parkinson's disease

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=77950223687&partnerID=8YFLogxK

U2 - 10.1093/brain/awq008

DO - 10.1093/brain/awq008

M3 - Article

C2 - 20157014

AN - SCOPUS:77950223687

VL - 133

SP - 713

EP - 726

JO - Brain

JF - Brain

SN - 0006-8950

IS - 3

ER -

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar 1;133(3):713-726. https://doi.org/10.1093/brain/awq008